NEXGEL's Growing Pains: Navigating a Post-Acquisition Maze

LANGHORNE, PA – August 17, 2026 – NEXGEL's latest financial report paints a picture of a company at a critical juncture, caught between the ambitious promise of strategic transformation and the messy reality of its execution. The hydrogel specialist reported second-quarter revenues of $3.69 million but posted a significant net loss of $2.87 million, a figure that underscores the immense operational and financial pressures it currently faces. The quarter was defined by the complex integration of assets acquired from Celularity, a process plagued by slower-than-expected progress and persistent supply chain bottlenecks that have left its new surgical division with a nearly $800,000 product backlog. While the company is making bold moves into higher-margin medical markets, it is simultaneously grappling with these operational hurdles and a recent, unexpected setback in a crucial shareholder vote, creating a complex narrative for investors to decipher.

The Price of Transformation: Unpacking the Financials

On the surface, NEXGEL's 27.8% year-over-year revenue growth appears robust, largely fueled by new sales from its biomaterials portfolio. However, the bottom line tells a different story. The $2.87 million net loss for the quarter is a stark contrast to the $665,000 loss in the same period last year. A closer look reveals that this loss is heavily weighted by costs associated with its strategic pivot. The company recorded approximately $1.17 million in non-recurring or non-cash charges, including $756,554 in amortization for the intangible assets from the BioNX acquisition, $273,710 in one-time transaction expenses, and a $144,495 charge for a strategic inventory recall. These figures highlight the immediate financial cost of long-term strategic repositioning.

Beneath these charges, the company's cash flow and liquidity position warrant close attention. NEXGEL's official filings reveal a "going concern" warning, signaling substantial doubt about its ability to continue operations without securing additional capital. The company ended the quarter with just $0.5 million in cash, having used $2.7 million in operating cash over the first six months of the year. While the post-quarter release of $710,000 in restricted cash provides some immediate relief, the company's ability to fund its ambitious growth plans hinges on future capital raises and the successful ramp-up of its new, higher-margin revenue streams. The investor update call planned for mid-September will be a critical moment for management to provide clarity on its path to sustainable profitability.

An Acquisition's Growing Pains

The centerpiece of NEXGEL's strategy is the integration of assets from Celularity, which formed the new BioNX Surgical division. This move was intended to catapult the company into the lucrative surgical market. However, the press release candidly admits that the rollout has been "slower than originally anticipated." The primary culprit appears to be a combination of integration friction and persistent supply chain challenges, which have culminated in a current BioNX Surgical backlog of approximately $795,000. This backlog is a double-edged sword: it confirms strong market demand for the new products but also lays bare the company's struggle to fulfill that demand.

To address the root cause of these supply chain issues, NEXGEL is executing a complex technology transfer. The plan involves moving manufacturing capabilities from Celularity's facility in New Jersey to a partner facility, Sequence Life Science, in Texas. This initiative, designed to improve long-term scalability, is now underway, with specialists deployed to facilitate the process. Still, it is a solution that will take time to implement fully, leaving the company to manage near-term product availability challenges while building a more resilient manufacturing backbone for the future. The pace of this transition will be a key determinant of NEXGEL's ability to convert its backlog into revenue in the coming quarters.

A Pivot to Higher Margins

Amidst the operational challenges, NEXGEL is executing a clear and deliberate pivot toward higher-value medical applications. The company made a notable move by recalling its SilverSeal wound care product from Amazon to prepare for a formal launch into the hospital market. This isn't a retreat, but a strategic redeployment. Management believes the hospital channel offers not only greater sales volume but also significantly higher gross margins than consumer-facing e-commerce. Crucially, SilverSeal already has established reimbursement A-codes, a key advantage that simplifies billing and encourages adoption in physician offices, ambulatory surgery centers, and hospitals by providing a clear pathway for payment.

This push into advanced wound care is complemented by an even more ambitious venture: the launch of BioNX Regenerative Eye Health & Aesthetics. This new initiative, leveraging products exclusively licensed from Sequence Life Science, aims to secure a foothold in the high-growth regenerative medicine space. By targeting ocular and aesthetic applications, NEXGEL is diversifying beyond its traditional hydrogel base into some of the most innovative and potentially profitable segments of healthcare. The company has tapped industry veteran Shaun Mullen to lead the charge, a move that lends significant credibility to the new division and signals a serious commitment to capturing a piece of this burgeoning market.

Corporate Governance and Capital Concerns

Adding another layer of complexity to the quarter was a surprising failure at the shareholder level. A proposal to increase the number of authorized shares and grant authority for a reverse stock split—both common corporate maintenance tasks often needed to support financing and Nasdaq listing requirements—failed to pass. Management attributed the failure to an unusually high level of "broker non-votes." The issue arose because these routine proposals were bundled with a more significant proposal to redomicile the company. This linkage prevented brokers from casting uninstructed votes in favor, a standard practice for uncontroversial items.

The setback has forced the company to go back to its shareholders. NEXGEL now plans to resolicit approval for the share increase and reverse split authority as standalone proposals, unburdened by the redomicile question. The company has engaged proxy solicitation firm Alliance Advisors to aid in this effort and expresses confidence that the proposals will pass on the second attempt. Management expects this to be resolved by late September, within a timeframe that should not derail its strategic objectives, but it served as a procedural stumble at a time when the company needs to project an image of flawless execution to the capital markets.